Press Releases

Press Releases

Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia Induced by Levodopa Therapy SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing
Multiple electrophysiological biomarkers indicate AV-101's NMDA receptor target engagement Both AV-101 doses were well-tolerated and not associated with dissociative or serious adverse events Poster presented at 2019 Annual Meeting of American College of Neuropsychopharmacology SOUTH SAN FRANCISCO,
VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline results from the
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the European Patent
Company on Track to Report Top Line Results Before Year End SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with
Company on Track to Report Topline Data Before Year End SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 15, 2019  /  VistaGen Therapeutics  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its fiscal
Previously completed Phase 2a clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration Phase 2b clinical trial for treatment of Major Depressive Disorder (MDD) planned for second half 2020
Displaying 71 - 80 of 199